Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Landmark Study Finds Pison AI Technology Can Detect Neurological Disorder in ALS Patients
Pison, the pioneers behind AI-powered neural biosensors for health, wellness, and 3D touchless smart device […]
Ocelot Bio Appoints Lise Kjems, M.D., Ph.D., as Chief Medical Officer
Ocelot Bio, a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics to treat […]
Daewoong Pharmaceutical and Sygnature Discovery Announce Drug Discovery Research Collaboration
Daewoong Pharmaceutical has entered a research collaboration with Sygnature Discovery to expand its global open […]
Precision BioSciences Announces Late-Breaking Abstract of Preclinical In Vivo Gene Editing Research for DMD
Precision BioSciences, a clinical-stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and […]
Gamida Cell’s Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) Receives FDA Approval
Gamida Cell, a cell therapy pioneer working to turn cells into powerful therapeutics, today announced […]
MapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors
MapKure, BeiGene and SpringWorks Therapeutics, today announced that they will present updated clinical data from the […]
NeoPhore Signs Research Collaboration with The Institute of Cancer Research, London
NeoPhore, a small molecule neoantigen immuno-oncology company, today announces that it has signed a strategic […]
FDA Approves QULIPTA® (atogepant) for Adults With Chronic Migraine
AbbVie today announced that the United States Food and Drug Administration (FDA) has approved expanding […]
Lipella Pharmaceuticals Enters Manufacturing Collaboration Agreement with Cook MyoSite
Lipella Pharmaceuticals, a clinical-stage biotechnology company addressing serious diseases with significant unmet need, has entered […]
Flare Therapeutics Presents First Preclinical Data on Lead Asset FX-909, a Novel Small Molecule PPARG Inhibitor to Potentially Treat Urothelial Cancer
Flare Therapeutics, a biotechnology company targeting transcription factors to discover precision medicines for cancer and […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more